The BLF Early COPD Development Partnership Grant
Most existing medical research has focused on patients with well-established COPD and poor lung function. Whilst this is important because such patients have lots of symptoms and problems, in some respects a better way of reducing health problems in the future would be to develop a strategy which focuses on patients with milder disease, and identifies which ones will go on to develop more severe problems and why these problems occur. The research in this application is designed to investigate these issues.
The main objective of the Partnership is to study the very early stages of the development of COPD. The investigators will do this by recruiting a novel cohort of smokers (age 30-45), in whom the investigators will follow the trajectories of lung function decline to identify prospectively those at risk of excess decline. This programme forms a unique UK consortium of 8 academic centres with excellent high quality publication records and broad experience in mechanistic, translational, clinical and epidemiological studies in COPD with key capabilities including primary care.
研究概览
地位
条件
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
-
London、英国
- Royal Brompton and Harefield NHS Foundation Trust
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
Subjects eligible for enrolment in the study must meet all the following criteria:
- Informed Consent: Subjects must give their signed and dated written informed consent to participate
- Gender: Male or female subjects
- Age: 30-45 years of age at screening
- Smokers of at least 10 pack years
- Have either normal lung function or mild lung function abnormalities
Subject groups will have one of the following:
- A. Subjects (smokers) with mild airflow limitation defined as an FEV1/FVC ratio <lower limit of normal and FEV1 > 80% of predicted normal and no symptoms. This group will make up at least 30% of the total cohort.
- B. Subjects (smokers) with mild airflow limitation as defined above and presence of respiratory symptoms defined as presence of chronic cough and/or chronic sputum and/or breathlessness equivalent to mMRC Grade 1 or higher. This group will make up no more than 25% of the total cohort.
- C. Subjects (smokers) with normal lung function defined as FEV1/FVC > lower limit of normal and FEV1 > 80% of predicted normal, with or without symptoms. This group will make up at least 30% of the total cohort.
Exclusion Criteria:
- Individuals currently diagnosed and treated for asthma will be excluded from the study, but individuals with a past history of childhood wheezing and of asthma may be included provided that they did not previously receive regular maintenance inhaled therapy with inhaled corticosteroids'
- Subjects with another known chronic respiratory disease - other than mild airflow limitation as defined above, predominantly cannabis or shisha smokers
- Subjects with autoimmune disease, diabetes, hypertension, thyroid disease or bronchiectasis, significant cardio-renal disease (including significant hypertension, atrial fibrillation, Hypertrophic Cardiomyopathy, significant cardiovascular disease), Malignancies.
- Clinically relevant abnormal laboratory values available at the screening assessment that could interfere with the objectives of the study or safety of the volunteer.
- Subjects who are actively enrolled in an interventional clinical trial
- Subjects with BMI >35
- Female participants who are pregnant or breastfeeding.
学习计划
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Annual change in lung function
大体时间：Three years
|
assessed by post-bronchodilator at 6 monthly intervals over a 3 year period.
|
Three years
|
|
Annual change in lung function
大体时间：Three years
|
assessed by body box plethysmography at 6 monthly intervals over a 3 year period.
|
Three years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Lung tissue attenuation and airway dimensions
大体时间：Three years
|
determined by CT-Scanning
|
Three years
|
|
Lung tissue attenuation and airway dimensions
大体时间：Three years
|
Assessed by full blood and differential counts
|
Three years
|
|
Lung tissue attenuation and airway dimensions
大体时间：Three years
|
Assessed by prevalence of chronic bronchitis as determined by MRC Bronchitis Questionnaire
|
Three years
|
|
Lung tissue attenuation and airway dimensions
大体时间：Three years
|
Assessed by respiratory symptoms, as determined by CAT Questionnaire
|
Three years
|
|
Lung tissue attenuation and airway dimensions
大体时间：Three years
|
Assessed by dyspnoea as determined by MRC Dyspnoa Scale
|
Three years
|
|
Lung tissue attenuation and airway dimensions
大体时间：Three years
|
Assessed by respiratory infections as determined by Respiratory Infection Questionnaire
|
Three years
|
|
Lung tissue attenuation and airway dimensions
大体时间：Three years
|
Assessed by depression and anxiety as determined by Hospital Anxiety Depression Scale
|
Three years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- IRAS Project ID: 206796
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.